how often to take semaglutide for weight loss Dosage Chart & Dosing Guide How Long Does It Take

DaVita (DVA) Q4 CY2025 Highlights: Revenue: $3.62 billion vs analyst estimates of $3.51 billion (9.9% year-on-year growth, 3.2% beat) Adjusted EPS: $3.40 vs analyst estimates of $3.19 (6.5% beat) Adjusted EBITDA: $772.8 million vs analyst estimates of $742 million (21.3% margin, 4.1% beat) Adjusted EPS guidance for the upcoming financial year 2026 is $14.30 at the midpoint, beating analyst estimates by 12.1% Operating Margin: 15.5%, down from 17.2% in the same quarter last year Sales Volumes were flat year on year, in line with the same quarter last year Market Capitalization: $7.85 billion StockStory's Take DaVita's fourth quarter results drew a positive market response, as the company outpaced Wall Street expectations on both revenue and non-GAAP profit

169 Baseline characteristics at diagnosis of T2D might be used to predict early glycemic deterioration followed by more aggressive interventions

Radiculopathy often produces numbness in specific patterns called dermatomes, which map to individual nerve roots

The telehealth company has integrated with both Novo Nordisk and Eli Lillys direct-to-consumer pharmacies

Glycemic targets: standards of medical care in diabetes-2020